资讯
Silent graft occlusion after coronary artery bypass grafting is detected before hospital discharge and is linked to ...
MyChesCo on MSN11 小时
XyloCor Doses First Patient in Pivotal Gene Therapy Trial for Refractory AnginaKING OF PRUSSIA, PA — XyloCor Therapeutics has dosed the first patient in its Phase 2b EXACT-2 trial evaluating XC001 (encoberminogene rezmadenovec), a novel gene therapy designed to help patients ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈